Droplet Digital Microfluidics Patents: Top Companies & Trends 2026
A patent landscape review of droplet digital microfluidics: who leads filings, how the field concentrates at the top, technology composition across IPC classes, and where filing activity is heading through 2026.
Filing growth = 2021 (110 records) → 2024 (34); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 873 records in scope (CR5), not the ranked leaders only.
What this landscape covers
Droplet digital microfluidics — the control of discrete droplets on electrode arrays or through channel networks for assay, sample-prep and point-of-care applications — sits at the intersection of lab hardware and molecular diagnostics claims. This landscape maps 873 published records filed or published between 2015 and the 2026-08-31 data cut-off, ranked by assignee, IPC subclass and receiving office. The search string captures both title-level references to droplet digital microfluidics and claim-level combinations of digital or droplet actuation with microfluidic or lab-on-a-chip terminology.
Because publication trails filing by roughly eighteen months, the last one to two years in any trend understate real filing activity. The figures below use 2024 as the most recent year treated as complete, and family-level counts where the ranking is concerned, since families are a fairer measure of filing effort than raw document counts inflated by continuations or multi-jurisdiction copies.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing concentration, technology mix and geography
The ranking below draws on all 873 records in scope. Five figures anchor the picture: how tightly filings concentrate among the ranked leaders, how the annual filing count has moved since 2015, which IPC subclasses carry the claim volume, and which receiving offices see the most filings.
Filing trend, 2017–2026
Annual filings rose to a peak of 110 in 2021, then declined to 34 by 2024 — a 69% drop over that three-year span. 2025 and 2026 figures are still filling in under the publication lag and should not be read as a continuing decline.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Technology composition by IPC subclass
B01L (lab apparatus) and G01N (material analysis and testing) each cover more than half of all 873 records, confirming that device mechanics and assay readout dominate claim language. Narrower classes such as B81B (MEMS structures), C12Q (enzyme/DNA testing) and B82Y (nanotechnology) mark smaller, more specialised filing pockets.
Shares are the percentage of the 873 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Lab-on-a-Chip & Microfluidics: Droplet Digital Microfluidics Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about lab-on-a-chip & microfluidics: droplet digital microfluidics patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative recent filing
US20250084439A1 — Systems and methods for applying voltages within droplet-based systems
The disclosure covers systems and methods for applying voltage or current within droplet-based systems, including to cause electroporation, by routing voltage to a target droplet via other droplets that are in physical or ionic contact with it. The approach is aimed at reducing electrode contamination, and describes droplets defined and controlled by pixels within a digital microfluidic device.Filed by DROPGENIE, INC., published 2025-03-13.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20020143437A1 | Methods and systems for control of microfluidic devices | 484 |
| 2 | US7010391B2 | Methods and systems for control of microfluidic devices | 299 |
| 3 | WO2011002957A2 | Droplet actuator devices and methods | 276 |
| 4 | WO2002078845A1 | Methods and systems for control of microfluidic devices | 224 |
| 5 | US20180095067A1 | Devices and methods for sample analysis | 208 |
| 6 | US20090203063A1 | Droplet-based cell culture and cell assays using digital microfluidics | 170 |
| 7 | WO2016161402A1 | Devices and methods for sample analysis | 155 |
| 8 | US20060021875A1 | Method, system, and program product for controlling chemical reactions in a digital microfluidic system | 154 |
| 9 | WO2016161400A1 | Devices and methods for sample analysis | 150 |
| 10 | US20130288254A1 | Droplet Actuator and Droplet-Based Techniques | 148 |
Citation counts favour older filings simply because they have had more time to accumulate citations inside the searched corpus — treat them as a signal of influence on later filers, not as a measure of which patents matter most today.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the concentration and composition figures mean for filing strategy
Three patterns stand out once the ranking, the technology mix and the citation table are read together: a leader with real but not exclusive control, a claim base still anchored in device mechanics, and a trend whose apparent slowdown needs the publication lag caveat before it is trusted.
The field has a leader, not a lock
The top-ranked assignee alone holds 142 records, and the top five combined reach 470 of 873 records in scope. That leaves roughly 46% of filings spread across a long tail, including single-filing entrants — there is room to build a position without displacing the leader outright.
Device mechanics still dominate claim language
B01L and G01N together cover the majority of records, meaning most claims still describe the actuation hardware or the analytical readout rather than novel assay chemistry. Narrower classes like C12Q and B82Y show where chemistry- or materials-specific claims are comparatively scarce.
Peak activity has passed — for now
Filings peaked in 2021 and fell 69% by 2024, the last year treated as complete under the roughly 18-month publication lag. Readings for 2025 and 2026 will keep filling in, so the recent drop should not yet be read as a permanent slowdown.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lab-on-a-chip & microfluidics: droplet digital microfluidics patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| BOE Technology Group Co., Ltd. | Beijing BOE Optoelectronics Technology Co., Ltd. | 21 |
| WHEELER AARON R | BARBULOVIC NAD IRENA | 10 |
| The Governing Council of the University of Toronto | Tecan Trading AG | 9 |
| WHEELER AARON R | YANG HAO | 9 |
| Nicoya Lifesciences Inc. | Nuclera Ltd. | 8 |
| The Governing Council of the University of Toronto | WHEELER AARON R | 7 |
| WHEELER AARON R | JEBRAIL MAIS J | 7 |
| The Governing Council of the University of Toronto | Sinai Health System | 6 |
Ten co-assignee pairs appear in the dataset, the strongest linking two BOE Technology entities on 21 shared records, followed by an academic-industry pairing (Wheeler and Barbulovic-Nad) at 10, and a university-industry pair (University of Toronto and Tecan Trading) at 9 — evidence that some of the leading filers build through joint academic or intra-group filing rather than solo prosecution.
Where to take this analysis
The figures above describe where filing has concentrated and where claim density is thin. Turning that into a filing or freedom-to-operate decision means going deeper into specific claim sets and specific assignees.
Map the claim boundaries of the most-cited records
The five most-cited records in this landscape, several tracing to a single litigation-tested family, set the boundaries that later filers had to design around. Reading their independent claims side by side shows exactly what is already occupied.
Explore in EurekaCheck a specific assignee's filing pattern
The ranking includes 100 companies; a leader at 142 records and a long tail below it means due diligence on any one competitor needs its own claim-by-claim read, not just a record count.
Explore in EurekaTrack the under-claimed IPC branches
Classes like B82Y and B01F sit under 4% of records each — worth a closer look before assuming the space is closed.
Explore in EurekaCommon questions about droplet digital microfluidics patents
One assignee leads the ranking with 142 records out of 873 in scope, well ahead of the fifth-ranked filer at 71. The top five combined account for 53.8% of all records, and the top ten reach 71.7%, so the field is concentrated but not a single-company monopoly. Below the top ten there is a long tail of assignees with far fewer filings each, including many single-filing entrants, which is where freedom-to-operate work usually needs the most care because those positions are less documented in aggregate rankings.
Filings peaked in 2021 at 110 records and fell to 34 by 2024, a 69% decline over that three-year span, which reads on its face like a cooling field. However, publication lags filing by roughly 18 months, so 2025 and 2026 figures are still incomplete and cannot yet be read as confirmation of a continuing slowdown. The honest read is that 2021 was a filing peak and 2024 is the most recent year with a reliable count; anything after that needs another year or two of publication catch-up before it is trustworthy.
The two largest IPC subclasses are B01L (lab apparatus), covering 61.3% of the 873 records, and G01N (material analysis and testing), covering 55.3%. Smaller but distinct pockets include B81B (microstructural/MEMS devices) at 15.0%, C12Q (enzyme and DNA testing) at 10.9%, and C12M (bioreactors and enzyme apparatus) at 9.4%. Since a single record can carry several IPC classes, these shares add up to more than 100% of the record total, and the pattern shows device and readout hardware claims outnumbering assay-chemistry-specific claims.
US20250084439A1, filed by DropGenie and published 2025-03-13, describes applying voltage or current to a target droplet indirectly, by routing it through other droplets that are in physical or ionic contact with the target, specifically to support electroporation while reducing electrode contamination. The droplets are defined and moved by pixels within a digital microfluidic device. It is a recent filing rather than one of the most-cited records in this dataset, so its influence on later filings is still developing, but it illustrates where claim activity is currently landing: indirect electrode addressing rather than direct-contact voltage application.
The United States receives the largest share of filings at 287, followed by WIPO PCT applications at 194 and the European Patent Office at 188. Canada, Australia and Germany follow at 67, 31 and 28 respectively. This spread indicates that most applicants are pursuing a US-first strategy with PCT and European coverage close behind, which is consistent with a field where several leading assignees are US- or Canada-based academic and diagnostics groups.
Research Lab-on-a-Chip & Microfluidics: Droplet Digital Microfluidics Patent Landscape in depth with Eureka
Go past this page: query the whole lab-on-a-chip & microfluidics: droplet digital microfluidics patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.